Halozyme Therapeutics, Inc 8-K, filed Sep 30, 2026
Halozyme Therapeutics, Inc. (HALO)
8-K
2026-09-30
For: 2026-09-28
View Original
Added on
September 30, 2026
About this 8-K
Halozyme Therapeutics, Inc filed this 8-K on September 30, 2026, reporting on events of September 28, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee. Mr. Daly will receive compensation for his services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time. The current components of the non-employee director compensation program were described in our proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026
There are no arrangements or understandings pursuant to which Mr. Daly was elected as a director and there are no related person transactions between the Company and Mr. Daly.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc (Registrant) | |||||||||||||||||
Dated: | September 30, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | |||||||||||||||||